undamentalytics Newsletter
Sign in

Relay Therapeutics, Inc. income statement

In fiscal 2025, Relay Therapeutics, Inc. reported revenue of $15.4m, up 53.4% on the year before, operating income of −$303m (a -1971.6% margin) and net income of −$276m, or −$1.61 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue833126101510
Research and development100173246330319261271
General and administrative39576675775750
Operating income−56−365−299−373−372−303−310
Income tax000000—
Net income−52−364−291−342−338−276−286
Diluted EPS−$5.40−$3.82−$2.59−$2.79−$2.36−$1.61−$1.57
Diluted shares (average)43m95m112m123m143m172m182m
EBITDA−52−361−295−368−367−299−308

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRBU vs RLAYIRD vs RLAYHYFT vs RLAYRLAY vs SRZN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Relay Therapeutics, Inc.